Arialys Therapeutics, a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, has appointed Peter Flynn, Ph.D., as President and Chief Executive Officer.   Flynn has more than 20 years of executive leadership experience in the biotech industry, from private start-ups to established publicly traded companies, scaling companies through key financings and pharma partnerships, advancing novel therapeutics from scientific breakthrough to the clinic, and commercial...